Benzinga | Jun 15, 2021 10:41AM EDT

Synlogic Says Presents Additional Preclincal Data On Therapeutic Candidates SYNB1934 For Phenylketonuria And SYNB8802 For Enteric Hyperoxaluria At Synthetic Biology: Engineering, Evolution & Design Conference

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicine(tm) SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934, an evolved strain of Synthetic Biotic medicine SYNB1618, for the treatment of Phenylketonuria (PKU) during the Synthetic Biology: Engineering, Evolution & Design (SEED) conference, being held virtually June 15-18, 2021.

The two posters will be available throughout the duration of the conference:

* Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU)

* Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria

SYNB1934 is an evolved strain of SYNB1618, developed to provide a potentially greater degree of phenylalanine (Phe)-lowering relative to SYNB1618. Data from preclinical in vivo and in vitro studies demonstrated a greater than 2-fold improvement in the ability of SYNB1934 to metabolize Phe compared to SYNB1618.

"The progression of SYNB1934 highlights Synlogic's ability to use synthetic biology to rapidly design and optimize Synthetic Biotic medicines with the potential for greater patient benefit. Building on SYNB1618, our team has iterated to generate a new fit-for-purpose strain. We look forward to continuing to progress SYNB1934 and to potentially providing people living with PKU new therapeutic options," said Dr. David Hava, Ph.D, Synlogic's Chief Scientific Officer.

SYNB8802 is an oral investigational drug for the treatment of Enteric Hyperoxaluria. The data presented characterizes in vitro and in vivo activity of SYNB8802 and, using proprietary gut simulation techniques, provides evidence of strain activity throughout the GI tract.